Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations
- PMID: 26711930
- DOI: 10.1016/j.lungcan.2015.11.006
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations
Abstract
Introduction: BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations are identified in approximately 2% of non-small cell lung cancer (NSCLC). Because of the rarity of those mutations, associated clinical features and prognostic significance have not been thoroughly described so far.
Methods: Here we took advantage of the French National Cancer Institute Program of systematic molecular profiling of metastatic lung cancer, to collect clinical characteristics and analyze the outcome of consecutive patients with NSCLC harboring BRAF mutations at the Lyon University Hospital laboratory between February 2012 and October 2014. Especially, we compared those variables with that of patients with EGFR-, BRAF-, KRAS-, HER2-, PIK3CA- wild-type NSCLCs.
Results: Among 2690 patients with genotyped NSCLC during the study period, BRAF mutations were identified in 80 (3%) cases, consisting of V600E substitution in 42 (53%) cases; non-V600E mutation were observed in 38 (48%) cases. Concurrent mutations were not observed in case of BRAF V600 mutation, and were identified in 5 patients with BRAF non-V600E mutations, in all cases consisting of KRAS mutations. Non-V600E mutations were more likely to be observed in smokers, as compared V600E mutations. There was no significant difference in age, histologic type, performance status, and stage at diagnosis between cases of V600E and non-V600E mutations. Overall survival did not significantly differ in BRAF wild-type, V600E, and non-V600E patients.
Conclusion: This one of the largest series of patients with BRAF mutant NSCLC. Our clinical data suggest that BRAF mutations define specific subsets of patients with NSCLC; while their oncogenic nature is yet to be established in lung cancer, especially for non-V600E mutations, the value of BRAF mutations to predict the efficacy of targeted agents remains unclear.
Keywords: BRAF mutations; EGFR mutations; Lung cancer; Smoking; V600E mutation.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618767611. doi: 10.1177/1753466618767611. Ther Adv Respir Dis. 2018. PMID: 29595366 Free PMC article. Review.
-
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.Eur J Cancer. 2019 Jul;116:86-97. doi: 10.1016/j.ejca.2019.04.016. Epub 2019 Jun 8. Eur J Cancer. 2019. PMID: 31181537
-
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.Cancer. 2015 Feb 1;121(3):448-56. doi: 10.1002/cncr.29042. Epub 2014 Oct 1. Cancer. 2015. PMID: 25273224 Free PMC article.
-
Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.Med Oncol. 2016 Oct;33(10):117. doi: 10.1007/s12032-016-0828-7. Epub 2016 Sep 16. Med Oncol. 2016. PMID: 27637917
-
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.ESMO Open. 2024 Oct;9(10):103935. doi: 10.1016/j.esmoop.2024.103935. Epub 2024 Oct 9. ESMO Open. 2024. PMID: 39389004 Free PMC article.
Cited by
-
[Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].Zhongguo Fei Ai Za Zhi. 2022 Feb 20;25(2):86-91. doi: 10.3779/j.issn.1009-3419.2021.101.51. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35224961 Free PMC article. Review. Chinese.
-
Capture of circulating metastatic cancer cell clusters from a lung cancer patient can reveal a unique genomic profile and potential anti-metastatic molecular targets: A proof of concept study.bioRxiv [Preprint]. 2023 Nov 7:2023.09.19.558270. doi: 10.1101/2023.09.19.558270. bioRxiv. 2023. Update in: PLoS One. 2024 Jul 31;19(7):e0306450. doi: 10.1371/journal.pone.0306450. PMID: 37781582 Free PMC article. Updated. Preprint.
-
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.Ther Adv Med Oncol. 2017 Jan;9(1):46-58. doi: 10.1177/1758834016670555. Epub 2016 Oct 3. Ther Adv Med Oncol. 2017. PMID: 28203297 Free PMC article. Review.
-
Protective Effects of Thymoquinon on Pulmonary Disorders in Experimental Studies.Tanaffos. 2018 Oct;17(4):211-222. Tanaffos. 2018. PMID: 31143211 Free PMC article. Review.
-
Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.Clin Lung Cancer. 2019 Mar;20(2):e208-e217. doi: 10.1016/j.cllc.2018.10.003. Epub 2018 Oct 23. Clin Lung Cancer. 2019. PMID: 30442523 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous